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Myocardial Metabolism for the
Toxicologist
by Robert G. Merin*
Drug effects on myocardial contractile function are obviously ofconsiderable practical importance for
the toxicologist. The basic mechanism of such actions must reside at some point in the metabolism of
cardiac muscle. Interference in the liberation of energy from the fuels that the heart uses may be
implicated. It is possible that drugs may interfere with the storage (conservation) of that energy as the
high energy phosphates (ATP and CP). Finally, the utilization of that stored energy by the contractile
proteins themselves may be altered. The latter process is highly dependent on intracelular calcium ion
kinetics. Anesthetic drugs, which produce reversible depression of myocardial contractile function is a
dose-dependent fashion, have been shown to interfere to some extent with all three processes. However,
the most important mechanism probably involves utilization of energy and intracellular calcium ion
movement. A basic knowledge ofthe biochemistry ofcardiac muscle is necessary for the understanding of
drug action and toxicity at the subcellular level.
My basic research interest inthe past 10 years has
centered on the effects of anesthetic drugs on car-
diac metabolism (1-5). I have been trying to corre-
late the depressant effects of anesthetics on ven-
tricular function with their effect on cardiac metab-
olism, coronary blood flow, and oxygenation. Al-
though I did not consider myself a toxicologist
heretofore, I suppose in a sense I have been study-
ing a "toxic" effect of anesthetics on the heart.
However, these negative inotropic effects are al-
most always reversible, and if not carried to ex-
treme, apparently leave no permanent sequellae. At
least this is true of the functional cardiac depres-
sion. In patients with ischemic heart disease, how-
ever, it is possible that a temporary decrease in
myocardial perfusion may result in sufficient de-
crease in oxygen delivery to produce permanent
damage in the form of myocardial infarction. Cer-
tainly these patients are at great risk for myocardial
infarction after anesthesia and surgery (6, 7). In ad-
dition to anesthetic effects on ventricular function
and myocardial perfusion and oxygenation, distur-
bances in heart rate and rhythm can also result in
"'cardiac toxicity." Inasmuch as the latter has not
been one of my major interests, I will not discuss
thisfurther, except to indicate that anumberofdrug
* Department of Anesthesiology, University of Rochester
Medical Center, Rochester, New York 14642.
Table 1. Cardiac toxicity: rate and rhythm.
Drugs Mechanism Duration
Anesthetics Overdose Usually transient
Cardioactive Overdose Usually transient
Cations Overdose Usually transient
(K+, Li+, Cae+)
ANS drugs Overdose Usually transient
Others (tricyclics, Overdose + ANS Usually transient
phenothiazines) effect
Table 2. Cardiac toxicity: ventricular function.
Drugs Mechanism Duration
Anesthetics Overdose Usually transient
Antiarrhythmics Overdose Usually transient
ANS drugs Overdose Usually transient
Anticancer Cardiomyopathy Permanent
(Adriamycin)
Methysergide Fibrosis + VHD Often permanent
Table 3. Cardiac toxicity: perfusion and oxygenation.
Drugs Mechanism Duration
Anesthetics 02 supply/demand Often permanent
ANS drugs 02 supply/demand Often permanent
Antihypertensives 02 supply/demand Often permanent
Oral contraceptives ? clotting abnormality Permanent
October 1978 169types can produce such toxicity (Table 1) (8, 9).
Likewise, several drug classes have been associated
with "toxic" effects on ventricular function (Table
2) and perfusion and oxygenation (Table 3) (8, 9).
Olson has divided the phases of cardiac energy
metabolism into three stages: (1) the liberation of
energy from the fuels the heart uses; (2) conserva-
tion of that energy as the high energy phosphates,
adenosine triphosphate (ATP), and creatine phos-
phate (CP); and (3) utilization of the energy by the
contractile proteins of cardiac muscle (Fig. 1) (10,
11). If a drug or chemical poisons cardiac contrac-
tile function, the subcellular mechanism must lie
somewhere within this inclusive schema.
Liberation of Energy
The heart is an aerobic organ. This is a conse-
quence of the efficiency of the oxidative pathways
of energy liberation and conservation as compared
with the only major anaerobic mechanism in heart
muscle, glycolysis. For example, 1 mole ofglucose
liberates 2 moles of ATP through anaerobic
glycolysis, while the same mole ofglucose can pro-
duce 36 moles of ATP through oxidative pathways
(12). Obviously then, the continual high energy de-
mands of the heart are best satisfied by the latter
and hence, oxygen is essential for adequate cardiac
function.
Heart muscle can liberate energy from numerous
fuel sources (Fig. 1). Free fatty acids, ketone
bodies, triglycerides, lactate, pyruvate, and glucose
can all be extracted from the blood by the heart if
the arterial concentrations are high enough. The
heart also stores and utilizes both lipids in the form
of triglycerides and carbohydrate as glycogen, al-
though not nearly as extensively as skeletal muscle
(13).
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FIGURE 1. Schema ofcardiac energetics. Cit = citrate; a-Keto =
a-ketoglutarate; Succ = succinate; Fum = Fumarate; Mal =
malate; AcCoA = acetyl Co A; OAA = oxalacetate; CP =
creatine phosphate; ATP = adenine triphosphate; ADP =
adenosine diphosphate. From Olsen et al. (11).
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FIGURE 2. Schema of oxidative metabolism in cardiac muscle:
(1-5) sites of hydrogen ion release for electron transport and
oxidative phosphorylation; (6) Site of "direct" production of
ATP; (a+ b) rate-limiting steps in TCA cycle. NAD =
nicotine adenine dinucleotide; FAD = flavin adenine dinu-
cleotide; TCA = tricarboxylic acid; ATP = adenosine triphos-
phate; ADP = adenosine diphosphate; Pi = inorganic phos-
phate; PDh = pyruvate dehydrogenase; IcDh = isocitric de-
hydrogenase; FPd = flavoprotein; ECF = extracellular fluid;
H+ = hydrogen ion.
Oxidative Metabolism
As mentioned before, all of these fuel sources
liberate the majority of their energy through oxida-
tive metabolism. Glucose and lactate are first con-
verted to pyruvate; the former through anaerobic
glycolysis, and the latterby oxidation, with nicotine
adenine dinucleotide (NAD)accepting the hydrogen
ion (Fig. 3). Thus this step for lactate is dependent
on oxygen for a continuing supply of NAD. The
next step is the formation of the two-carbon frag-
ment, acetyl Co-A (Fig. 2). For both lipids and car-
bohydrates, the conversion takes place in the
mitochondria. Pyruvate is converted to acetyl Co-A
by the action of the enzyme complex known as
pyruvate dehydrogenase in the outer mitochondrial
membrane (14). The fatty acids are activated with
Co-enzyme A to acyl Co-A and transported across
the mitochondrial membrane by the 7-carbon or-
ganic acid, carnitine (Fig. 2). Acyl-Co-A is then beta-
oxidized, catalyzed by an enzyme complex in a
manner analogous to pyruvate dehydrogenase, to
the same acetyl Co-A, which then combines with
oxaloacetate to begin the tricarboxcylic acid (TCA)
cycle. The actual liberation of energy and conser-
vation as ATPoccurs at six points inthe TCAcycle;
direct phosphorylation of succinyl-Co-A is respon-
sible for 1 mole ofATP; 3 moles NADH and 1 mole
FADH2 are produced in the TCA cycle, and 1 mole
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FIGURE 3. Schema ofglycolysis: c-AMP = cyclic 3-5-adenosine
monophosphate; G-6-P = glucose 6-phosphate; F-6-P =
fructose 6-phosphate; PFK = phosphofructokinase; F-1,6-P
= fructose 1,6-diphosphate; G-3-P = glycerol 3-phosphate;
G3-PDh = glycerol 3-phosphodehydrogenase; 1-3-DPG =
1,3-diphosphoglycerate; ADP = adenosine diphosphate; Pi =
inorganic phosphate; 3-DPG = diphosphoglycerate; 2-DPG =
2-diphosphoglycerate; P-E-pyruvate = phosphoenol pyru-
vate; P-Dh = pyruvate dehydrogenase NAD = nicotine
adenine dinucleotide; ECF = extra-cellular fluid.
NADH is generated by the oxidation ofpyruvate to
acetyl Co-A (Fig. 2). These hydrogens then com-
bine with oxygen along the electron transport chain,
catalyzed by the various cytochrome and flavopro-
tein enzymes to form ATP and water. Several moles
of ATP are produced by each of the oxidations
through oxidative phosphorylation. The control of
oxidative metabolism is governed primarily by the
availability of substrate and oxygen (both for the
final electron transport and for the oxidation of
NADH to provide NAD for the continuing activity
of the TCA cycle). In addition, the products of
energy utilization, adenosine diphosphate (ADP),
adenosine monophosphate (AMP), and inorganic
phosphate (Pi) stimulate the rate-limiting enzymes
in the TCA cycle, isocitric dehydrogenase (Fig. 2b)
and pyruvate dehydrogenase (Fig. 2a). Finally, the
electron transport chains themselves may be inhib-
ited oruncoupled by various drugs and chemicals.
Glycolysis
The only mechanism by which heart muscle can
liberate energy anaerobically is through the
Embden-Meyerhof glycolytic pathway (Fig. 3).
Either glycogen or glucose may be broken down to
pyruvate, producing 4 moles of ATP per mole of
glucose (orglucose-I-phosphate from glycogen) at a
cost of 2 moles of ATP without molecular oxygen.
The first rate-limiting step in this process is the
membrane passage of glucose which is normally
insulin-dependent (Fig. 3). However, hypoxia in the
absence ofinsulin will also stimulate the membrane
transport of glucose. The next rate-limiting step is
the conversion of fructose-6-phosphate to
fructose-1-6-diphosphate, catalyzed by the enzyme
phosphofructokinase (PFK). This enzyme is re-
sponsive to the energy balance ofthe heart. Excess
ATP and CP inhibits its activity, decreasing
glycolysis, and rising levels of ADP, AMP and Pi
stimulate the enzyme, increasing glycolytic pro-
duction of energy. Cyclic AMP stimulates, and hy-
drogen ion inhibits PFK, providing influences out-
side the actual energy supply-demand relationship.
As mentioned, the pyruvate-lactate balance is ex-
quisitely sensitive to the oxygen supply, with
hypoxia driving the reaction towards lactate pro-
duction. Hypoxia actually stimulates the whole
glycolytic pathway (membrane transport and PFK),
producing increasing amounts ofpyruvate. In addi-
tion, metabolic oxygen is necessary forthe oxidized
NAD concerned in the conversion of pyruvate to
acetyl Co-A. Hypoxia markedly inhibits this con-
version (in spite of the stimulation of pyruvate de-
hydrogenase by ADP, AMP, and Pi) and without
metabolic oxygen, the electron transport chain and
the TCA cycle grind to a halt, increasing acetyl
Co-A levels and further inhibiting pyruvate oxida-
tion. Consequently, the concentration of pyruvate
builds, driving the pyruvate-lactate reaction to-
wards lactate. The end result is lactate production
by hypoxic heart muscle, whereas the well oxyge-
nated heart efficiently uses lactate. Finally in the
ischemic heart, however, inhibition of glycolysis
occurs. This is a result of the build-up of hydrogen
ion and NADH resulting in the inhibition ofthe en-
zyme glyceraldehyde-3-phosphate dehydrogenase
(G-3-PDh) (13). Under normal circumstances, this
step is not rate-limiting, but the mechanism appears
to be important in the ischemic heart.
Glycogen and Triglycerides
As mentioned above, the heart stores fuel from
glucose as glycogen and from fatty acids as tri-
glycerides. The control ofthese processes is still not
well delineated, but it appears that insulin directly
stimulates the synthesis of glycogen and promotes
esterification of fatty acids to triglycerides by sup-
October 1978 171pressing lipolysis. The best documented stimulus to
glycogenolysis and lipolysis is cyclic 3-5 AMP pro-
duced primarily by beta adrenergic stimulation but
perhaps by other mechanisms as well (glucagon and
growth hormone). In general increased energy de-
mand by the heart will stimulate oxidation of both
glycogen and triglycerides. Unlike skeletal muscle,
however, cardiac muscle stores relatively little fuel,
uses it only in times of great stress, and rapidly
depletes the stores, relying predominantly on exog-
enous fuel sources (13).
Conservation (Storage) of Energy
Heart (and skeletal) muscle obtain their energy
for contraction through the hydrolysis of ATP,
which is generated in the mitochondria as we have
discussed, and appears to be utilized in the interac-
tion of actin and myosin. The heart stores this
energy both as ATP and CP, with the latter serving
as a buffer store. CP is rapidly and easily converted
to ATP by reaction with the ADP generated from
ATP hydrolysis, stimulated by creatine-
phosphokinase (CPK). A further mechanism of
maintaining stable ATP level is through the forma-
tion of ATP directly from ADP catalyzed by the
enzyme myokinase (15). Theoretically, interference
with energy liberation and conservation should re-
sult in decreased tissue high energy phosphate
levels, and block in energy utilization should lead to
no change or an increase in CP and ATP concentra-
tions. However, as indicated in the previous sec-
tion, the control of myocardial energy supply is
tightly linked to the levels ofATP, ADP, AMP, and
Pi levels, as they exert the major controls on both
glycolysis and oxidative metabolism. Hence, heart
muscle attempts to maintain these levels constant
even in face of influences to the contrary.
Utilization of Energy
The whole purpose of energy liberation and con-
servation is the interaction of the contractile pro-
teins which are the basis for the contractile function
of the heart. Although much is known about the
anatomy and physiology of these subcellular com-
ponents ofthe muscle cell, some ofwhat I will dis-
cuss below is still supposition and hypothesis as
concerns cardiac muscle.
The two basic contractile proteins are the "thin"
actinfiament andthe "thick" myosinfilament (Fig.
4). Myosin is composed ofathick stalk and globular
heads which contain the ATPase and the actin-
binding sites. Myosin ATPase is relatively inactive
and, although sensitive to calcium, cannot develop
the requisite activity to hydrolyze sufficient ATP
for the energy needs of contracting muscle. Only
when the cross-bridging (binding) to actin has oc-
curred does the enzyme become sufficiently active
for this purpose (when stimulated by calcium ion).
The thin actin filament is composed of a double
helix ofactin globules, with a long thin tropomyosin
protein located in the helical grove. At intervals
along the tropomyosin corresponding roughly to the
location of the projecting myosin heads, another
protein, troponin, is bound to tropomyosin. This
association is crucial to the control of contractile
function. During rest (diastole in the heart), the
troponin-tropomyosin complex inhibits actin-
myosin crossbridging (Fig. 4). When the muscle cell
membrane (sarcolemma) is activated by an action
potential, the membranes barrier to calcium ion is
temporarily removed, and the high extracellular
calcium ion concentration provides a gradient for
intracellular influx, probably triggering further re-
lease of an intracellular calcium ion store. Sarco-
plasmic calcium ion level rises rapidly from less
than 10-7M (the level during relaxation) to some-
where between 10-6 and 10-5M. Calcium ion binds
to the troponin-tropomyosin complex, releasing the
inhibition of the myosin binding site, and
crossbridging occurs, resulting in tension develop-
ment and shortening of the muscle (Fig. 4). The
rising calcium ion concentration also stimulates the
actomyosin ATPase activity so that ATP hydrolysis
may release the requisite energy for contraction.
The source of this intracellular calcium ion is still
controversial. It may be from the sarcoplasmic re-
ticular (SR) membrane system as in skeletal muscle.
However, SR is much less abundant and widely
distributed in cardiac muscle, so it may be that cal-
cium ion is released from sarcolemmal binding sites
(16, 17). In order for the cardiac cycle to be com-
pleted, the crossbridging must be broken, and the
muscle must relax. It seems likely that active
sequestration of calcium ion is necessary to lower
sarcoplasmic calcium ion concentration back to less
than 10-7M in the short time available. Both SR and
mitochondrial membranes possess the requisite en-
zyme and transport systems for this function.
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FIGURE 4. Schematic ofcontractile proteins. Ca2+ = calcium ion;
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with the sparse SR and abundant sarcolemma in the
form of the T-tubular system suggest that the cal-
cium ion release and sequestration process may be
predominantly a function of the sarcolemma.
Site of Action of Drugs
Calcium ion is central to this whole process (Fig.
5), releasing the inhibition of the troponin-
tropomyosin mechanism so that actin-myosin
crossbridging can take place, stimulating the ac-
tomyosin ATPase so that energy may be utilized for
contraction, and possibly stimulating the reuptake
of sarcoplasmic calcium ion which is necessary for
relaxation and the recurrent cardiac cycle. Con-
sequently, it is not surprising that some interference
with calcium ion kinetics has been suggested as a
locus of action of anesthetic drugs (18). Likewise,
the calcium-sensitive ATPase as a crucial part of
energy utilization may also be involved (19). Inter-
ference in energy liberation and supply is also pos-
sible, although the evidence seems less convincing
at present (18-22). The most likely sites for drug or
chemical action would be at the rate-limiting steps
(Figs. 2 and 3), although anesthetics (20) and several
known poisons (rotenone, cyanide) interfere with
electron transport systems assistance or uncouple
oxidative phosphorylation.
Myocardial Perfusion and
Metabolism
As emphasized previously, the heart needs con-
tinuous oxygen supply in order to function effi-
ciently. The components of this supply include
adequate arterial oxygen content and sufficient
arterial blood pressure to provide enough coronary
Pi
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FIGURE 6. Myocardial oxygen supply and demanddeterminants.
blood flow against the coronary vascular resistance
(Fig. 6). The crucial factor is the balance between
myocardial oxygen supply and demand. Ifboth are
increased or decreased in concert, then there is no
imbalance. This is the function ofthe autoregulation
of coronary blood flow which is controlled pre-
dominantly by alterations in coronary vascular re-
sistance. Increasing oxygen demand results in
coronary vasodilation, probably through the activ-
ity ofthe breakdown products ofATP (adenosine or
possibly AMP) (23). Decreasing demand means
more ATP and coronary vasoconstriction (or at
least reversal of vasodilation). In addition, one of
the major causes ofincreased demand, sympathetic
stimulation, may also produce beta adrenergically
mediated coronary vasodilation, although this is a
controversial subject (24).
Although decreased arterial oxygen content can
cause myocardial tissue hypoxia, as long as blood
viscosity is not too high (for instance, as a result of
polycythemia from chronic hypoxia), amazingly
low arterial oxygen contents can cause little func-
tional impairment because of marked coronary
vasodilation and increased coronary blood flow.
The most common cause of myocardial tissue
hypoxia is myocardial ischemia as found in is-
chemic heart disease as a result of coronary
atherosclerosis. In this pathogenic situation, normal
coronary autoregulation is ineffective because of
the fixed coronary arterial obstruction. Hence de-
crease in arterial driving pressure, or increase in the
determinants of oxygen demand (heart rate,
myocardial wall tension, and contractile perfor-
mance of the heart) (Fig. 6) can result in cardiac
toxicity manifested as myocardial infarction. For
investigational purposes, it is important to be able
to detect such an imbalance before actual tissue
death. As mentioned during the discussion of
glycolysis, hypoxic heart muscle will produce lac-
tate in contrast to well oxygenated tissue which ex-
tracts it. Other markers in coronary venous blood of
tissue hypoxia include increasing concentrations of
potassium, Pi, and the purine metabolites, inosine
and hypoxanthine (25). Other methods of detecting
cardiac tissue hypoxic injury include electrocar-
diographic ST segment analysis, nuclear scanning
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173techniques, and elevation of the mb-CPK isoen-
zyme (26). Thus far, the effect of anesthetics on
myocardial oxygenation in both normal (2, 5, 20, 27)
and ischemic (28) hearts appears to be related
primarily to effects on oxygen demand. However, it
is entirely possible that drugs and chemicals may
specifically interfere with oxygen supply. Ergot de-
rivatives (29) and vasopressin both can produce
coronary vasoconstriction and uncouple the
myocardial oxygen supply demand ratio. It is possi-
ble that substances may affect oxyhemoglobin as-
sociation or dissociation thereby interfering with
oxygen delivery. In order to uncover these effects,
some method of quantitating myocardial tissue
oxygenation must be used. Merely documentating
the determinants of oxygen supply and demand is
not sufficient.
Conclusion
Only by knowledge and review ofthe biochemis-
try and physiology of cardiac energetics and con-
tractile function can the likely sites for the effect of
toxic substances on this function be identified. This
review, although necessarily superficial, is meant to
stimulate interest. For actual projects, obviously
considerably more resource material will be neces-
sary. Hopefully, this is only the beginning.
This study was supported in part by Grant HL13257 and Re-
search Career Development Award 31752, National Heart, Lung
and Blood Institute.
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